1. QUESTION
===========

What is the role of oxaliplatin combined with 5-fluorouracil (5-[fu]{.smallcaps}) and folinic acid ([fa]{.smallcaps}) in the first- and second-line treatment of advanced (unresectable locally advanced or metastatic) colorectal cancer?

Outcomes of interest were 1-year survival, response rates, and quality of life ([qol]{.smallcaps}).

2. CHOICE OF TOPIC AND RATIONALE
================================

In Ontario, Canada, colorectal cancer is the fourth most common cancer site for both sexes combined, representing 13.1% of all new cancer cases [@b1-co13_5p173]. Colorectal cancer is the third most common site in men (13.3% of all new cases) and the second most common site in women (12.9% of all new cases) [@b1-co13_5p173], and it remains the second leading cause of cancer death (10.6% of all cancer deaths) [@b1-co13_5p173]. Considering both men and women, colorectal cancer ranks third as the leading cause of death after breast and lung cancers in females and after lung and prostate cancers in males [@b1-co13_5p173]. For that reason, interest in improving the treatment results for this group of patients is great.

Currently, the standard first-line treatment for metastatic colorectal cancer ([mcc]{.smallcaps}) in Canada is a combination of 5-[fu]{.smallcaps}, [fa]{.smallcaps} \[also known as leucovorin calcium ([lv]{.smallcaps})\], and irinotecan---called [folfiri]{.smallcaps}---delivered by infusion (Douillard regimen)[@b2-co13_5p173]. Infusional [folfiri]{.smallcaps} replaced [ifl]{.smallcaps}, which is the same drug combination by bolus delivery. For patients unable to tolerate a combination-therapy regimen, an alternative to [folfiri]{.smallcaps} is monotherapy with a first-line thymidylate synthase ([ts]{.smallcaps}) inhibitor such as 5-[fu]{.smallcaps}/[lv]{.smallcaps}, raltitrexed [@b3-co13_5p173], or capecitabine, followed by second-line irinotecan alone [@b4-co13_5p173].

Once patients are no longer responding to the combined use of a [ts]{.smallcaps} inhibitor and irinotecan or to monotherapy, the options for treatment are limited. Oxaliplatin, a third-generation platinum compound has demonstrated activity in colorectal cancer. Oxaliplatin differs from both cisplatin and carboplatin in its amino acid configuration. Oxaliplatin has an oxalato group that is removed by hydrolysis and replaced with a diaminocyclohexane ([dach]{.smallcaps}) group[@b5-co13_5p173]. The bulky [dach]{.smallcaps} side groups inhibit [dna]{.smallcaps} base excision by mismatching the repair enzymes [@b5-co13_5p173]. Because repair enzymes are particularly active in colorectal cancer, oxaliplatin has the potential to be of great benefit to patients in both first- and second-line treatment. With the availability of randomized trials comparing combination regimens of oxaliplatin and 5-[fu]{.smallcaps}/[fa]{.smallcaps} with other combinations, a systematic review of the evidence and clinical practice guideline were warranted.

3. METHODS
==========

3.1 Guideline Development
-------------------------

This systematic review was developed by the Gastrointestinal Cancer Disease Site Group ([gi dsg]{.smallcaps}) of Cancer Care Ontario's Program in Evidence-Based Care ([pebc]{.smallcaps}), using the methods of the practice guidelines development cycle [@b6-co13_5p173]. Evidence was selected and reviewed by two members of the [gi dsg]{.smallcaps} and by a methodologist.

The body of evidence in this review is primarily composed of data from mature randomized controlled trials ([rct]{.smallcaps}s). The systematic review and clinical practice guideline are intended to promote evidence-based practice in Ontario, Canada. The [pebc]{.smallcaps} is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

3.2 Literature Search Strategy
------------------------------

A systematic search of the [medline]{.smallcaps} \[1966 to June (week 1) 2006\], [cancerlit]{.smallcaps} (1975 to October 2002), [embase]{.smallcaps} (week 26, 2003, to week 23, 2006), Guidelines International Network, and Cochrane Library (through Issue 1, 2006) databases was conducted in June 2006. The Medical Subject Heading search terms "colonic neoplasms," "rectal neoplasms," and "colorectal neoplasms" were combined with the text words "oxaliplatin", "[l]{.smallcaps}-[ohp]{.smallcaps}," "[lohp]{.smallcaps}," and "[folfox]{.smallcaps}". The results from that search were then combined with the terms "random" and "clinical trial" describing specific study designs. Results were limited to the English language. The conference proceedings of the 1999 to 2006 annual meetings of the American Society of Clinical Oncology, including the 2004 through 2006 gastrointestinal cancer symposia, were also searched for reports of new or ongoing trials. The reference lists from retrieved papers were searched for additional trials.

3.3 Study Selection Criteria
----------------------------

Articles were selected for inclusion in this systematic review of the evidence if they were

-   phase [iii rcts]{.smallcaps} of oxaliplatin ([l]{.smallcaps}-[ohp]{.smallcaps}) combined with 5-[fu]{.smallcaps}/[fa]{.smallcaps} as first-line or second-line therapy for advanced colorectal cancer.

-   abstract reports of trials.

-   English-language published reports.

3.4 Synthesizing the Evidence
-----------------------------

For the following reasons, the [gi dsg]{.smallcaps} decided not to pool the results of the trials found in the literature search:

-   Treatments described were too heterogeneous to allow for pooling.

-   Evidence from the studies obtained provided a clear indication of benefit or harm.

-   Published meta-analyses of individual patient data were available. (The meta-analyses are discussed in the appropriate sections of this report.)

4. RESULTS
==========

4.1 Literature Search Results
-----------------------------

The literature search found thirty-three reports [@b7-co13_5p173]--[@b39-co13_5p173], including twenty-seven reports on randomized controlled trials ([rcts]{.smallcaps}) of first-line treatment [@b7-co13_5p173]--[@b16-co13_5p173],[@b18-co13_5p173]--[@b27-co13_5p173],[@b31-co13_5p173]--[@b37-co13_5p173], involving seventeen separate [rct]{.smallcaps}s [@b7-co13_5p173]--[@b16-co13_5p173],[@b31-co13_5p173]--[@b37-co13_5p173]; two meta-analyses on first-line treatment [@b28-co13_5p173],[@b29-co13_5p173]; and four reports on second-line treatment [@b17-co13_5p173],[@b30-co13_5p173],[@b38-co13_5p173],[@b39-co13_5p173]. Ten of these reports were preliminary publications that provided additional information about the included trials [@b18-co13_5p173]--[@b27-co13_5p173]. Of the thirty-three trial reports obtained, twelve were fully published [@b7-co13_5p173],[@b8-co13_5p173],[@b10-co13_5p173],[@b11-co13_5p173],[@b15-co13_5p173],[@b16-co13_5p173],[@b28-co13_5p173],[@b31-co13_5p173],[@b32-co13_5p173],[@b34-co13_5p173],[@b35-co13_5p173],[@b37-co13_5p173], and twenty-one were available in abstract form only [@b9-co13_5p173],[@b12-co13_5p173]--[@b14-co13_5p173],[@b17-co13_5p173]--[@b27-co13_5p173],[@b29-co13_5p173],[@b30-co13_5p173],[@b33-co13_5p173],[@b36-co13_5p173],[@b38-co13_5p173],[@b39-co13_5p173]. Of the seventeen main reports on first-line treatment, six were available as abstracts only [@b9-co13_5p173],[@b12-co13_5p173]--[@b14-co13_5p173],[@b33-co13_5p173],[@b36-co13_5p173]. All four reports on second-line treatment were available as abstracts only [@b17-co13_5p173],[@b30-co13_5p173],[@b38-co13_5p173],[@b39-co13_5p173].

Sixteen of the included trial reports disclosed funding, either wholly or in part, from pharmaceutical companies [@b7-co13_5p173],[@b8-co13_5p173],[@b10-co13_5p173],[@b11-co13_5p173],[@b15-co13_5p173]--[@b17-co13_5p173],[@b20-co13_5p173]--[@b22-co13_5p173],[@b27-co13_5p173],[@b30-co13_5p173],[@b31-co13_5p173],[@b39-co13_5p173]. Seven reported Debiopharm as the source of funding [@b7-co13_5p173],[@b8-co13_5p173],[@b10-co13_5p173],[@b11-co13_5p173],[@b20-co13_5p173]--[@b22-co13_5p173]; one reported Pharmacia (Pfizer)/Sanofi--Synthelabo [@b15-co13_5p173]; two reported Aventis [@b16-co13_5p173],[@b27-co13_5p173]; one reported Aventis / Sanofi--Synthelabo [@b31-co13_5p173]; and three reported Sanofi--Synthelabo [@b17-co13_5p173],[@b30-co13_5p173],[@b39-co13_5p173]. Five of the reports disclosed a hospital, university, research group, or another non-industry entity as the source of funding [@b32-co13_5p173]--[@b35-co13_5p173],[@b37-co13_5p173], and twelve trials did not report the source of funding [@b9-co13_5p173],[@b12-co13_5p173]--[@b14-co13_5p173],[@b18-co13_5p173],[@b19-co13_5p173],[@b23-co13_5p173]--[@b26-co13_5p173],[@b36-co13_5p173],[@b38-co13_5p173]. The reported sources of funding for the two obtained meta-analyses were a research group grant [@b28-co13_5p173] and partial industry funding [@b29-co13_5p173].

4.2 Outcomes
------------

### 4.2.1 Phase [iii]{.smallcaps} RCTs of Oxaliplatin Combined with 5-FU and FA as First-line Therapy for Advanced Colorectal Cancer

Twenty-seven reports [@b7-co13_5p173]--[@b16-co13_5p173],[@b18-co13_5p173]--[@b27-co13_5p173],[@b31-co13_5p173]--[@b37-co13_5p173] of [rcts]{.smallcaps} on first-line treatment, representing seventeen individual trials [@b7-co13_5p173]--[@b16-co13_5p173], [@b31-co13_5p173]--[@b37-co13_5p173] were obtained ([Table I](#tI-co13_5p173){ref-type="table"}). Six reports of these seventeen trials were available in abstract form only [@b9-co13_5p173],[@b12-co13_5p173], [@b13-co13_5p173],[@b14-co13_5p173],[@b33-co13_5p173],[@b36-co13_5p173]. Results for the outcomes of interest follow.

#### 1-Year Survival

Only seven of the seventeen trials reported 1-year survival data [@b8-co13_5p173],[@b10-co13_5p173],[@b11-co13_5p173],[@b15-co13_5p173],[@b31-co13_5p173],[@b32-co13_5p173],[@b35-co13_5p173]. One of the trials [@b8-co13_5p173] compared two regimens that both contained 5-[fu]{.smallcaps}, [fa]{.smallcaps}, and oxaliplatin: one in a standard infusion, and the other in a chronomodulated regimen. Both arms reported similar 1-year survival rates (66% vs. 63%, *p* \> 0.05). Of the other six trials, only two detected statistically significant 1-year survival differences: one for [folfox]{.smallcaps}4 over [ifl]{.smallcaps} (71% vs. 58%, *p* = 0.002) [@b15-co13_5p173], and another for [oxafafu]{.smallcaps} over [irifafu]{.smallcaps} (39% vs. 23%, *p* = 0.032) [@b31-co13_5p173].

#### Response Rates

Only two of the seventeen trials did not report data on response rates [@b9-co13_5p173],[@b12-co13_5p173]. Nine of the 15 trials reported statistically significant differences (*p* \< 0.05) in response rates between treatment arms: three for chronomodulated regimens of 5-[fu]{.smallcaps}, [fa]{.smallcaps}, and oxaliplatin over standard infusion regimens of the same agents [@b7-co13_5p173],[@b8-co13_5p173],[@b11-co13_5p173]; and the others for [lv]{.smallcaps}5[fu]{.smallcaps}2 and oxaliplatin over [lv]{.smallcaps}5[fu]{.smallcaps}2 alone [@b10-co13_5p173]; for [fufox]{.smallcaps} over [fufa]{.smallcaps} [@b13-co13_5p173]; for [folfox]{.smallcaps}4 over [ifl]{.smallcaps} and for [irox]{.smallcaps} over [ifl]{.smallcaps} [@b15-co13_5p173]; for both low- and high-dose [oxafafu]{.smallcaps} over [irifafu]{.smallcaps} [@b31-co13_5p173]; for [folfoxiri]{.smallcaps} over [folfiri]{.smallcaps} [@b33-co13_5p173]; and for [oxafafu]{.smallcaps} over [fafu]{.smallcaps}[@b34-co13_5p173]. One trial that reported on response rates did not report a *p* value [@b36-co13_5p173]. Three trials reported no significant difference between treatment arms: [folfox]{.smallcaps} and [folfiri]{.smallcaps} [@b14-co13_5p173], [folfox]{.smallcaps}4 and [irox]{.smallcaps} [@b15-co13_5p173], and the crossover trial by Tournigand *et al.* [@b16-co13_5p173] that compared the sequences [folfiri]{.smallcaps}→[folfox]{.smallcaps}6 and [folfox]{.smallcaps}6→[folfiri]{.smallcaps}.

#### Quality of Life

Only two of the seventeen [rcts]{.smallcaps} reported data on [qol]{.smallcaps} [@b10-co13_5p173],[@b34-co13_5p173]. Of these latter two trials, neither reported a significant difference in [qol]{.smallcaps} scores between the trial arms: [lv]{.smallcaps}5[fu]{.smallcaps}2 plus oxaliplatin versus [lv]{.smallcaps}5[fu]{.smallcaps}2 [@b10-co13_5p173], or [oxafafu]{.smallcaps} versus [fafu]{.smallcaps} [@b33-co13_5p173].

As reported in the [rcts]{.smallcaps} located by the literature search, first-line treatment with oxaliplatin was associated with significantly more peripheral and sensory neuropathy and neutropenia beyond the adverse effects expected with the other drugs given in the regimen.

### 4.2.2 Meta-analyses of First-line Trials

The meta-analysis reported by Grothey *et al.* [@b28-co13_5p173] included the fully published or publicly presented results from seven [rcts]{.smallcaps} involving 3186 patients. It detected a significant 3.5-month increase in median survival (*p* = 0.0083) in patients who received a first-line combination therapy (either oxaliplatin/5-[fu]{.smallcaps}/[fa]{.smallcaps} or irinotecan/5-[fu]{.smallcaps}/[fa]{.smallcaps}) as compared with patients who received monotherapy. The results of the meta-analysis indicated that, for maximum overall survival benefit, patients on a first-line combination therapy containing oxaliplatin should be offered combination therapy with irinotecan as second-line treatment, and vice versa. It appears that second-line treatment may compensate for a less active first-line treatment, as evidenced by the fact that patients who had access to all three active drugs (oxaliplatin, irinotecan, and 5-[fu]{.smallcaps}) showed the longest overall survival. However, this conclusion is confounded by the fact that patients who lived longer were more likely to have been treated with all three drugs. In addition, patients with lower performance status may have been excluded from second-line treatments using oxaliplatin and irinotecan. Additionally, oxaliplatin was not available to all patients, especially in older trials. The meta-analysis detected longer median survival times in more recent trials---trials more likely to use oxaliplatin in first- and second-line treatment.

An abstract report by Lévi *et al.* [@b29-co13_5p173] pooled the 7-year results of two previously discussed, but individually underpowered, trials [@b7-co13_5p173],[@b8-co13_5p173]. Both trials compared chronomodulated ([cm]{.smallcaps}) infusion to flat infusion in the first-line treatment of [mcc]{.smallcaps}. Significant benefits were detected in overall response rate ([orr]{.smallcaps}%: 51% vs. 30%; *p* \< 0.001), complete surgical resection (23.3% vs. 12.8%, *p* \< 0.001), and median progression-free survival ([pfs]{.smallcaps}: 10.3 months vs. 7.5 months; *p* = 0.039) favouring [cm]{.smallcaps} therapy; however, no difference was detected in median survival (18.6 months vs. 16.5 months, *p* = 0.22). Pooling the data from the two trials did not detect any difference in survival at either 5 or 7 years (5-year survival: 12.6% vs. 15.2%; 7-year survival: 6.6% vs. 7.1%). The results may have been confounded by an imbalance between the studies with regard to recurrent metastatic disease following surgery for liver metastases (10% of patients receiving flat infusion vs. 22% of patients receiving [cm]{.smallcaps} infusion, *p* \< 0.001), and in addition, by significant treatment crossover from the flat infusion to the [cm]{.smallcaps} infusion arm (26% of patients), which affected median survival (14.7 months non-crossover vs. 18.5 months crossover; *p* = 0.043). The pooled results from those two trials confirmed that, as compared with flat infusion, [cm]{.smallcaps} infusion significantly improved the [orr]{.smallcaps}% and [pfs]{.smallcaps}.

### 4.2.3 Phase III RCTs of Oxaliplatin Combined with 5-FU and FA as Second-line Therapy for Advanced Colorectal Cancer

Four reports [@b17-co13_5p173],[@b30-co13_5p173],[@b38-co13_5p173],[@b39-co13_5p173] describing four [rct]{.smallcaps}s of second-line treatment were obtained ([Table I](#tI-co13_5p173){ref-type="table"}). All of these trial reports were available in abstract form only.

#### 1-Year Survival

None of the second-line treatment reports obtained provided data on 1-year survival.

#### Response Rates

Three of the four reports [@b17-co13_5p173],[@b30-co13_5p173],[@b39-co13_5p173] provided data on response rates. All three trials reported statistically significant differences between the trial arms, two for [folfox]{.smallcaps}4 over [lv]{.smallcaps}5[fu]{.smallcaps}2 [@b17-co13_5p173],[@b30-co13_5p173] (9.9% vs. 0%, *p* \< 0.0001 [@b30-co13_5p173]; 11.1% vs. 1.9%, *p* \< 0.05 [@b17-co13_5p173]), and the third for the sequence [folfox]{.smallcaps}4→[cpt]{.smallcaps}-11 over [cpt]{.smallcaps}-11→ [folfox]{.smallcaps}4 (27% vs. 15%, *p* \< 0.0142)[@b39-co13_5p173].

#### Quality of Life

None of these abstract reports provided data on [qol]{.smallcaps}.

As indicated under the heading "Quality of Life" in subsection 4.2.1, treatment with oxaliplatin was associated with significantly more peripheral and sensory neuropathy and neutropenia beyond the adverse effects expected from other drugs given in the regimen.

5. INTERPRETIVE SUMMARY
=======================

The combination regimens using infusional 5-[fu]{.smallcaps} ([folfox]{.smallcaps} or [folfiri]{.smallcaps}) both represent acceptable treatment alternatives for first-line therapy in fit patients.

Oxaliplatin is active in colorectal cancer, and the evidence supports its use in combination with infusional 5-[fu]{.smallcaps}/[fa]{.smallcaps} ([folfox]{.smallcaps}). Oxaliplatin without 5-[fu]{.smallcaps}/[fa]{.smallcaps} does not appear to have meaningful activity. The [folfox]{.smallcaps} regimen has definite advantages over bolus [ifl]{.smallcaps} in terms of toxicity, objective response rate (45% vs. 31%), median [ttp]{.smallcaps} (8.7 months vs. 6.9 months), median survival (19.5 months vs. 15.0 months), and 1-year survival (71% vs. 58%) as demonstrated in the N9741 study [@b15-co13_5p173].

The superior 1-year survival seen in the N9741 study may have two possible explanations:

-   The 5-[fu]{.smallcaps} was given as an infusion in the [folfox]{.smallcaps} arm, but as a bolus in the [ifl]{.smallcaps} arm, and infusional 5-[fu]{.smallcaps} has demonstrated superiority over bolus 5-[fu]{.smallcaps} in terms of toxicity and tumour response rate. This fact alone may therefore account for the differences seen in the two regimens. It may also account for the lack of difference seen between [folfox]{.smallcaps} and [folfiri]{.smallcaps} in the [gercor]{.smallcaps} study, because both regimens used infusional 5-[fu]{.smallcaps} [@b16-co13_5p173].

-   Superior survival in the [folfox]{.smallcaps} arm may relate to the high rate of second-line irinotecan use. In the [folfox]{.smallcaps} arm, 53% of the patients received second-line irinotecan, but only 17% of patients on the [ifl]{.smallcaps} arm received second-line oxaliplatin. It is becoming increasingly clear that subsequent therapy can have a substantial effect on survival. From the evidence reviewed, it appears that the number of active drugs available to a study arm may positively affect survival, because when more drugs are made available to patients, median survival is increased. This finding does not rule out other factors, such as variations in study population and other variations in treatment over time, but it is highly supportive of the conclusion that access to all three active drugs (5-[fu]{.smallcaps}/[fa]{.smallcaps}, oxaliplatin, irinotecan) is important to optimize patient outcomes [@b27-co13_5p173]. It is also evident that when combination therapy is to be used, infusional rather than bolus 5-[fu]{.smallcaps} should be used. This recommendation to use 5-[fu]{.smallcaps} in an infusional schedule is now abundantly clear from single-agent studies, from combination studies in advanced disease, and from the adjuvant setting in early colorectal cancer. The role of bolus 5-[fu]{.smallcaps} in the management of colorectal cancer is becoming increasingly limited.

The combination of oxaliplatin and irinotecan is also active, but it has lower tumour response rates and 1-year survival rates than [folfox]{.smallcaps} does, and therefore no advantages [@b15-co13_5p173].

The inconvenience of infusional 5-[fu]{.smallcaps} pump programs, in combination with the drug's unavailability in certain regions, has led to interest in oral capecitabine as a possible replacement for infusional 5-[fu]{.smallcaps} in oxaliplatin and irinotecan combinations. The few phase [ii]{.smallcaps} trials reported thus far have demonstrated response rates and toxicity that appear comparable to those seen with infusional 5-[fu]{.smallcaps} combinations. In the future, capecitabine may supersede the 5-[fu]{.smallcaps} pump and the need for central venous access devices; however, this development will depend on the results of ongoing phase [iii]{.smallcaps} trials. Until the results of those trials are available, infusional 5-[fu]{.smallcaps} regimens---either alone or in combination---are standard therapy.

The question of whether to use a [cm]{.smallcaps} regimen of infusional 5-[fu]{.smallcaps} is a compelling area of study, but no such regimen has been widely evaluated outside of a few specialized centres. This question extends beyond a simple review of 5-[fu]{.smallcaps}/oxaliplatin combinations. The pooled analysis of the two underpowered studies by Lévi *et al.* [@b7-co13_5p173],[@b8-co13_5p173] suggests that [cm]{.smallcaps} could both reduce toxicity and positively affect endpoints such as [orr]{.smallcaps}% and [ttp]{.smallcaps}. The intervention is worthy of further study, although the complexity of the therapy may put it beyond feasibility in many locales.

The ECF4584 trial [@b30-co13_5p173] demonstrated improvements in response rate, [ttp]{.smallcaps} (median: 4.6 months vs. 1.6 months, *p* \< 0.0001), and symptom control with second-line [folfox]{.smallcaps} as compared with oxaliplatin alone or infusional 5-[fu]{.smallcaps}/[fa]{.smallcaps} alone in patients who progressed on the [ilf]{.smallcaps} regimen. No overall survival analysis was performed. For patients who have progressed on both an anti-[ts]{.smallcaps} agent and irinotecan, [folfox]{.smallcaps} is the preferred therapy.

In patients with tumour progression on first-line 5-[fu]{.smallcaps}/[fa]{.smallcaps}, [folfox]{.smallcaps} is active, with an [orr]{.smallcaps}% that appears to compare favourably with that of [folfiri]{.smallcaps}, the standard regimen. Currently, more evidence supports second-line irinotecan than supports [folfox]{.smallcaps} or oxaliplatin alone, but for patients considered poor candidates for second-line irinotecan, [folfox]{.smallcaps} is a reasonable alternative. Further clarification of the role of oxaliplatin after progression on first-line 5-[fu]{.smallcaps} awaits more-mature data from the Sanofi-sponsored ECF4585 trial.

As treatment regimens for advanced colorectal cancer continue to evolve, recent trials [@b38-co13_5p173],[@b40-co13_5p173] have investigated the addition of bevacizumab to the [folfox]{.smallcaps} regimen. An abstract report by Hochster *et al.* [@b40-co13_5p173] of the [tree]{.smallcaps}-2 study---a first-line cohort study comparing [folfox]{.smallcaps} plus bevacizumab, [oxafafu]{.smallcaps} plus bevacizumab, and capecitabine and oxaliplatin ([capox]{.smallcaps}) plus bevacizumab---found that [folfox]{.smallcaps} plus bevacizumab resulted in the longest median survival with acceptable adverse events. In the [tree]{.smallcaps}-2 study, the median survivals for the treatment arms without bevacizumab were 19.2 months ([folfox]{.smallcaps}), 17.9 months ([oxafafu]{.smallcaps}), and 17.3 months ([capox]{.smallcaps}) as compared with 26 months ([folfox]{.smallcaps} + bevacizumab), 20.7 months ([oxafafu]{.smallcaps} + bevacizumab), and 27.0 months ([capox]{.smallcaps} + bevacizumab) [@b41-co13_5p173]. The overall median survival was 18.2 months (no bevacizumab) as compared with 24.4 months (bevacizumab added) [@b41-co13_5p173]. When the overall survival data from the [tree]{.smallcaps}-1 trial (no bevacizumab) were compared with the [tree]{.smallcaps}-2 trial data (bevacizumab added), the results were 12 months, 67.5% versus 79.1%; 18 months, 50.1% versus 64.7%; 24 months, 35.8% versus 50.7%---all in favour of the treatments including bevacizumab [@b41-co13_5p173].

The second-line [rct]{.smallcaps} reported by Giantonio *et al.* [@b38-co13_5p173], which compared [folfox]{.smallcaps}4 with and without bevacizumab, found that the addition of bevacizumab to the [folfox]{.smallcaps} regimen resulted in significant gains in both median survival (10.7 months vs. 10.2 months, *p* = 0.0024) and [pfs]{.smallcaps} (7.4 months vs. 5.5 months, *p* = 0.0003). Based on these two trials, we conclude that the addition of bevacizumab to an infusional 5-[fu]{.smallcaps}, [fa]{.smallcaps}, and oxaliplatin regimen may provide benefits beyond those that would be possible with infusional 5-[fu]{.smallcaps}, [fa]{.smallcaps}, and oxaliplatin without bevacizumab.

6. GASTROINTESTINAL CANCER DSG CONSENSUS PROCESS
================================================

Note
----

The [gi dsg]{.smallcaps} consensus process was based on an earlier draft of the present document. That draft did not contain any of the evidence regarding the addition of bevacizumab to regimens of infusional 5-[fu]{.smallcaps}/[fa]{.smallcaps} plus oxaliplatin. References [@b15-co13_5p173] and [@b31-co13_5p173]--[@b41-co13_5p173] were added to the document after the consensus process took place.

The systematic review found one first-line therapy trial [@b15-co13_5p173] that demonstrated infusional 5-[fu]{.smallcaps}/[fa]{.smallcaps}/ oxaliplatin ([folfox]{.smallcaps}) to be superior to bolus 5-[fu]{.smallcaps}/[fa]{.smallcaps}/ irinotecan ([ifl]{.smallcaps}), with more favourable rates of median survival and tumour response. Compared with [ifl]{.smallcaps}, [folfox]{.smallcaps} has lower incidences of severe nausea, vomiting, diarrhea, and febrile neutropenia, but a higher incidence of peripheral neuropathy. Therefore, for first-line treatment, short-term infusional 5-[fu]{.smallcaps}/[fa]{.smallcaps} in combination with either oxaliplatin ([folfox]{.smallcaps}) or irinotecan ([folfiri]{.smallcaps}) is acceptable for fit patients when combination therapy is the preferred treatment. Choice of first-line therapy may rely on patient factors and preferences---for example, less neuropathy with irinotecan versus less alopecia with oxaliplatin.

For second-line treatment after progression on first-line anti-[ts]{.smallcaps} monotherapy (for example, 5-[fu]{.smallcaps}/[fa]{.smallcaps}, capecitabine), irinotecan is standard therapy. For patients with contraindications to the use of second-line irinotecan, [folfox]{.smallcaps} is a reasonable alternative. After progression on both irinotecan and an anti-[ts]{.smallcaps} agent, [folfox]{.smallcaps} is the preferred therapy.

The role of radiation therapy, either alone or in combination with chemotherapy, for locally advanced unresectable colorectal cancer was not addressed in this guideline. In addition, the use of [cm]{.smallcaps} regimens is a topic that intersects with the use of oxaliplatin/5-[fu]{.smallcaps} combinations, particularly [cm]{.smallcaps} 5-[fu]{.smallcaps} in those combinations. Chronomodulation of oxaliplatin has not been extensively studied and was not addressed, because the topic is beyond the scope of this guideline.

In conclusion, the [gi dsg]{.smallcaps} acknowledges that the combination of oxaliplatin with short-term infusional 5-[fu]{.smallcaps} and [fa]{.smallcaps} ([folfox]{.smallcaps}) is an important component of first- and second-line treatment of advanced colon cancer, and the [dsg]{.smallcaps} recommends that oxaliplatin be made available for the treatment of advanced colorectal cancer.

7. EXTERNAL REVIEW OF THE PRACTICE GUIDELINE REPORT
===================================================

Note
----

The practitioner feedback survey was based on an earlier draft of the present document. That draft did not contain any of the evidence regarding the addition of bevacizumab to infusional regimens of 5-[fu]{.smallcaps}/[fa]{.smallcaps} plus oxaliplatin. References [@b15-co13_5p173] and [@b31-co13_5p173]--[@b41-co13_5p173] were added to the document after the practitioner feedback survey was complete.

Based on the evidence and the draft recommendations presented at the time of [gi dsg]{.smallcaps} consensus, feedback was sought from Ontario clinicians.

7.1 Methods
-----------

Practitioner feedback was obtained through a mailed survey of 63 practitioners in Ontario (11 medical oncologists, 9 radiation oncologists, 42 surgeons, and one other practitioner). The survey consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and asking whether the draft recommendations should be approved as a practice guideline. Written comments were invited. The practitioner feedback survey was mailed September 15, 2004. Follow-up reminders were sent at 2 weeks (post card) and 4 weeks (complete package mailed again). The [gi dsg]{.smallcaps} reviewed the results of the survey.

7.2 Results
-----------

From among the 63 surveys distributed, 29 responses were received (46% response rate). "Responses" include returned completed surveys and telephone, fax, and e-mail responses. Of the practitioners who responded, 18 indicated that the report was relevant to their clinical practice, and they completed the survey. [Table II](#tII-co13_5p173){ref-type="table"} summarizes key results of the practitioner feedback survey.

7.3 Summary of Written Comments
-------------------------------

Four respondents (22%) provided written comments. The main points were these:

-   Access issues with oxaliplatin are ongoing.

-   The guidelines seem to be directed to the medical oncologists who provide the treatments. For other caregivers in the cancer system, this key message needs to be delivered: Cancer treatment is in a state of continuous development with increasing efficacy, therefore assessment by a medical oncologist is important for all patients.

-   Some of the stated recommendations are currently in use and are being accepted with enthusiasm by both clinicians and patients.

-   This guideline has not included any information regarding the role of radiation in the local management of rectal tumours. However, the guideline makes good sense with respect to the recommended chemotherapy regimens. Could a recommendation, or at least a comment, be added somewhere in the document regarding radiation timing, and radiation in combination with the recommended chemotherapy regimens?

7.4 Modifications/Actions
-------------------------

The [gi dsg]{.smallcaps} made the following modifications to the clinical practice guideline in response to the comments obtained during practitioner feedback:

-   With respect to the ongoing access issues with oxaliplatin, the [gi dsg]{.smallcaps} acknowledges the major barrier that access represents to putting its recommendations into practice. The [gi dsg]{.smallcaps} hopes that their recommendation of oxaliplatin will raise awareness of the issue and facilitate the process of making this drug available to patients.

-   With respect to the issue of radiation therapy, the [gi dsg]{.smallcaps} added a qualifying statement to both the abstract and the main document: "The role of radiation therapy, either alone or in combination with chemotherapy, for locally advanced unresectable colorectal cancer is not addressed in this guideline."

Figures and Tables
==================

###### 

Phase III trials of oxaliplatin combined with 5-fluorouracil (5-[fu]{.smallcaps}) and folinic acid ([fa]{.smallcaps}) as first-line therapy for advanced colorectal cancer

  *Reference*                                                                  *Regimen*                                                          *Patients (*n*)*   *[orr]{.smallcaps}(%[cr]{.smallcaps}+[pr]{.smallcaps})*   *Disease stabilization (%)*   *Median[ttp]{.smallcaps}(months)*   *Median[pfs]{.smallcaps}(months)*   *Median survival (months)*      *Median follow-up time (months)*   *1-Year survival (%)*
  ---------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------ --------------------------------------------------------- ----------------------------- ----------------------------------- ----------------------------------- ------------------------------- ---------------------------------- -----------------------------------------------
  First-line treatment                                                                                                                                                                                                                                                                                                                                                                                  
   Lévi *et al.*, 1994, France [@b7-co13_5p173]                                5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin                    47                 32 (2+13)                                                 45                            [nr]{.smallcaps}                    8                                   14.9                            30                                 [nr]{.smallcaps}
                                                                               [cm]{.smallcaps} 5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin   45                 53 (3+21)                                                 33                            [nr]{.smallcaps}                    11                                  19                                                                 [nr]{.smallcaps}
                                                                                                                                                                     *p*=0.038                                                 *p*=[nr]{.smallcaps}                                              *p*=[nr]{.smallcaps}                *p*=0.03                                                           
   Lévi *et al.*, 1997, France [@b8-co13_5p173]                                5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin                    93                 29 (3+24)                                                 [nr]{.smallcaps}              4.9                                 7.9                                 16.9                            36                                 66
                                                                               [cm]{.smallcaps} 5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin   93                 51 (5+42)                                                 [nr]{.smallcaps}              6.4                                 9.8                                 15.9                                                               63
                                                                                                                                                                     *p*\<0.0001                                                                             *p*=0.006                           *P*=[NS]{.smallcaps}                *p*=[ns]{.smallcaps}                                               *p*=[ns]{.smallcaps}
   Buechele *et al.*, 2000,                                                    5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin                    [nr]{.smallcaps}   [nr]{.smallcaps}                                          [nr]{.smallcaps}              [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
   Germany [@b9-co13_5p173] (abstract)                                         5-[fu]{.smallcaps}/[fa]{.smallcaps}                                [nr]{.smallcaps}   [nr]{.smallcaps}                                          [nr]{.smallcaps}              [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
   de Gramont *et al.*, 2000,                                                  [lv]{.smallcaps}5[fu]{.smallcaps}2/oxaliplatin                     210                50.7 (3+102)                                              31.9                          [nr]{.smallcaps}                    9                                   16.2                            27.7                               69
   France [@b10-co13_5p173]                                                    [lv]{.smallcaps}5[fu]{.smallcaps}2                                 210                22.3 (1+45)                                               51.0                          [nr]{.smallcaps}                    6.2                                 14.7                                                               61
                                                                                                                                                                     *p*=0.0001                                                *p*=[nr]{.smallcaps}                                              *p*=0.0001                          *p*=0.05                                                           *p*=[ns]{.smallcaps}
   Giachetti *et al.*, 2000,                                                   [cm]{.smallcaps} 5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin   100                53 (3+50)                                                 24                            [nr]{.smallcaps}                    8.7                                 19.4                            47                                 75[a](#tfn1-co13_5p173){ref-type="table-fn"}
   France [@b11-co13_5p173]                                                    [cm]{.smallcaps} 5-[fu]{.smallcaps}/[fa]{.smallcaps}               100                16 (0+16)                                                 45                            [nr]{.smallcaps}                    6.1                                 19.9                                                               71[a](#tfn1-co13_5p173){ref-type="table-fn"}
                                                                                                                                                                     *p*\<0.0001                                               *p*=[nr]{.smallcaps}                                              *p*=0.48                            *p*=[ns]{.smallcaps}                                               *p*=[ns]{.smallcaps}
   Giachetti *et al.*, 2002,                                                   [cm]{.smallcaps} 5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin   250                [nr]{.smallcaps}                                          [nr]{.smallcaps}              [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
   France [@b12-co13_5p173] (abstract, [eortc]{.smallcaps} trial)              5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin                    250                [nr]{.smallcaps}                                          [nr]{.smallcaps}              [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
   Grothey *et al.,* 2002 [@b13-co13_5p173] (abstract)                         [fufa]{.smallcaps} (Mayo)                                          124                22.6                                                      [nr]{.smallcaps}              [nr]{.smallcaps}                    5.3                                 16.1                            27.3                               [nr]{.smallcaps}
                                                                               [fufox]{.smallcaps}                                                114                48.3                                                      [nr]{.smallcaps}              [nr]{.smallcaps}                    7.9                                 20.4                                                               [nr]{.smallcaps}
                                                                                                                                                                     *p*\<0.0001                                                                                                                 *p*\<0.0001                         *p*=[nr]{.smallcaps}                                               
   Colucci *et al.,* 2003 [@b14-co13_5p173] (abstract)                         [folfox]{.smallcaps}                                               145                36                                                        39                            [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               [folfiri]{.smallcaps}                                              178                34                                                        44                            [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                                                                                                                     *p*=[ns]{.smallcaps}                                      *p*=[nr]{.smallcaps}                                                                                                                                                     
   Goldberg *et al.,* 2004 [@b15-co13_5p173] (Intergroup N9741)                \(A\) [folfox]{.smallcaps}4                                        267                45                                                        [nr]{.smallcaps}              8.7                                 [nr]{.smallcaps}                    19.5                            [nr]{.smallcaps}                   71[a](#tfn1-co13_5p173){ref-type="table-fn"}
                                                                               \(B\) [ifl]{.smallcaps}                                            264                31                                                        [nr]{.smallcaps}              6.9                                 [nr]{.smallcaps}                    15.0                            [nr]{.smallcaps}                   58 [a](#tfn1-co13_5p173){ref-type="table-fn"}
                                                                               \(C\) [irox]{.smallcaps}                                           264                35                                                        [nr]{.smallcaps}              6.5                                 [nr]{.smallcaps}                    17.4                            [nr]{.smallcaps}                   65 [a](#tfn1-co13_5p173){ref-type="table-fn"}
                                                                                                                                                                     A vs. B: *p*\<0.05                                                                      A vs. B: *p*\<0.05                                                      A vs. B: *p*\<0.05                                                 A vs. B: *p*=0.002
                                                                                                                                                                     B vs. C: *p*\<0.05                                                                      B vs. C: *p*\<0.05                                                      B vs. C: *p*\<0.05                                                 B vs. C: *p*=[ns]{.smallcaps}
                                                                                                                                                                     A vs. C: *p*=[ns]{.smallcaps}                                                           A vs. C: *p*=[ns]{.smallcaps}                                           A vs. C: *p*=[ns]{.smallcaps}                                      A vs. C: *p*=[ns]{.smallcaps}
   Tournigand *et al.,* 2004 [@b16-co13_5p173] ([gercor]{.smallcaps})          [folfiri]{.smallcaps}→[folfox]{.smallcaps}6                        109                56 (3+58) 1st line                                        23 1st line                   [nr]{.smallcaps}                    8.5 1st line                        21.5                            43.9                               [nr]{.smallcaps}
                                                                                                                                                                     15 (0+12) 2nd line                                        48 2nd line                                                       4.2 2nd line                                                                                           
                                                                               [folfox]{.smallcaps}6 →[folfiri]{.smallcaps}                       111                54 (5+54) 1st line                                        27 1st line                   [nr]{.smallcaps}                    8.0 1st line                        20.6                                                               [nr]{.smallcaps}
                                                                                                                                                                     4 (0+3) 2nd line                                          30 2nd line                                                       2.5 2nd line                                                                                           
                                                                                                                                                                     *P*=[NS]{.smallcaps}                                      *p*=[nr]{.smallcaps}                                                                                  *p*=[ns]{.smallcaps}                                               
   Comella *et al.,* 2005 [@b31-co13_5p173] ([sicog]{.smallcaps})              [irifafu]{.smallcaps}                                              135                31 (16+26)                                                27                            7.9                                 5.8                                 15.6                            24                                 23
                                                                               [oxafafu]{.smallcaps} high-dose                                    71                 41 (7+22)                                                 21                            10.5                                                                    17.6                                                               
                                                                               [oxafafu]{.smallcaps} low-dose                                     68                 47 (13+19)                                                22                            7.9                                 7.0                                 23+                                                                39
                                                                                                                                                                     *p=*0.029                                                                                                                                                                                                                          *p=*0.032
   Colucci *et al.,* 2005 [@b32-co13_5p173] ([goim]{.smallcaps})               [folfiri]{.smallcaps}                                              178                34 (8+48)                                                 42                            7                                   [nr]{.smallcaps}                    14                              31                                 55
                                                                               [folfox]{.smallcaps}4                                              182                36 (9+53)                                                 38                            7                                   [nr]{.smallcaps}                    15                                                                 62
                                                                                                                                                                     *p=*0.60                                                                                                                                                                                                                           *p\>*0.05
   Falcone *et al.,* 2006 [@b33-co13_5p173] ([gono]{.smallcaps}, abstract)     [folfoxiri]{.smallcaps}                                            122                66                                                        [nr]{.smallcaps}              [nr]{.smallcaps}                    9.8                                 22.6                            15.2                               [nr]{.smallcaps}
                                                                               [folfiri]{.smallcaps}                                              122                41                                                        [nr]{.smallcaps}              [nr]{.smallcaps}                    6.9                                 16.7                                                               [nr]{.smallcaps}
                                                                                                                                                                     *p=*0.0002                                                                                                                  *p=*0.0006                          *p=*0.032                                                          
   Hospers *et al.,* 2006[@b34-co13_5p173]                                     [oxafafu]{.smallcaps}                                              151                33.8                                                      43                            [nr]{.smallcaps}                    6.7                                 13.8                            31.8                               [nr]{.smallcaps}
                                                                               [fafu]{.smallcaps}                                                 151                18.5                                                      50.3                          [nr]{.smallcaps}                    5.6                                 13.3                                                               [nr]{.smallcaps}
                                                                                                                                                                     *p=*0.004                                                                                                                                                                                                                          
   Souglakos *et al.,* 2006[@b35-co13_5p173] ([horg]{.smallcaps})              [folfoxiri]{.smallcaps}                                            137                43 (9+50)                                                 [nr]{.smallcaps}              8.4                                 [nr]{.smallcaps}                    21.5                            26                                 67
                                                                               [folfiri]{.smallcaps}                                              146                33.6 (5+44)                                               [nr]{.smallcaps}              6.9                                 [nr]{.smallcaps}                    19.5                                                               64
                                                                                                                                                                     *p=*[ns]{.smallcaps}                                                                    *p=*[ns]{.smallcaps}                                                    *p=*[ns]{.smallcaps}                                               *p=*[ns]{.smallcaps}
   Stanculeanu *et al.,* 2006 [@b36-co13_5p173] (abstract)                     [folfox]{.smallcaps}4                                              22                 64 (2+12)                                                 27.3                          [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               [folfiri]{.smallcaps}                                              18                 44 (1+7)                                                  44.4                          [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               [irox]{.smallcaps}                                                 17                 53 (2+7)                                                  35.3                          [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                                                                                                                     *p=*[nr]{.smallcaps}                                                                                                                                                                                                               
   Tournigand *et al.,* 2006 [@b37-co13_5p173] ([gercor]{.smallcaps})          [folfox]{.smallcaps}4                                              311                58.5                                                      [nr]{.smallcaps}              [nr]{.smallcaps}                    9                                   19.3                            31                                 [nr]{.smallcaps}
                                                                               [folfox]{.smallcaps}7                                              309                59.2                                                      [nr]{.smallcaps}              [nr]{.smallcaps}                    8.7                                 21.2                                                               [nr]{.smallcaps}
                                                                                                                                                                     *p=*[ns]{.smallcaps}                                                                                                                                                                                                               
  Second-line treatment                                                                                                                                                                                                                                                                                                                                                                                 
   Rothenberg *et al.,* 2003 [@b30-co13_5p173] (abstract, EFC4584)             [lv]{.smallcaps}5[fu]{.smallcaps}2                                 256                0                                                         [nr]{.smallcaps}              2.7                                 [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               Oxaliplatin                                                        266                [nr]{.smallcaps}                                          [nr]{.smallcaps}              [nr]{.smallcaps}                    [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               [folfox]{.smallcaps}4                                              267                9.9                                                       [nr]{.smallcaps}              4.6                                 [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                                                                                                                     *p*\<0.0001                                                                             *p*\<0.0001                                                                                                                                
   Garay *et al.,* 2003 [@b17-co13_5p173] (abstract)                           [folfox]{.smallcaps}4                                              105                11.1                                                      [nr]{.smallcaps}              4.9                                 [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               [lv]{.smallcaps}5[fu]{.smallcaps}2                                 101                1.9                                                       [nr]{.smallcaps}              2.6                                 [nr]{.smallcaps}                    [nr]{.smallcaps}                [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                                                                                                                     *p*\<0.05                                                                               *p*\<0.05                                                                                                                                  
   Giantonio *et al.,* 2005 [@b38-co13_5p173] (abstract, [ecog]{.smallcaps})   \(A\) [folfox]{.smallcaps}4+bevacizumab                            290                [nr]{.smallcaps}                                          [nr]{.smallcaps}              [nr]{.smallcaps}                    7.4                                 12.5                            [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               \(B\) [folfox]{.smallcaps}4                                        289                [nr]{.smallcaps}                                          [nr]{.smallcaps}              [nr]{.smallcaps}                    5.5                                 10.7                            [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               \(C\) Bevacizumab                                                  243                [nr]{.smallcaps}                                          [nr]{.smallcaps}              [nr]{.smallcaps}                    3.5                                 10.2                            [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                                                                                                                                                                                                                                                 A vs. B: *p=*0.0003                 A vs. B: *p=*0.0024                                                
   Pitot *et al.,* 2005 [@b39-co13_5p173] (abstract, N9841)                    [cpt]{.smallcaps}-11→[folfox]{.smallcaps}4                         245                15                                                        [nr]{.smallcaps}              4.0                                 [nr]{.smallcaps}                    14.7                            [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                               [folfox]{.smallcaps}4→[cpt]{.smallcaps}-11                         246                27                                                        [nr]{.smallcaps}              5.2                                 [nr]{.smallcaps}                    13.5                            [nr]{.smallcaps}                   [nr]{.smallcaps}
                                                                                                                                                                     p\<0.01                                                                                                                                                                                                                            

Estimated from survival curve.

[orr]{.smallcaps} = overall response rate; [cr]{.smallcaps} = complete response; [pr]{.smallcaps} = partial response; [ttp]{.smallcaps} = time to progression; [pfs]{.smallcaps} = progression-free survival; [nr]{.smallcaps} = not reported; [cm]{.smallcaps} = chronomodulated delivery rate; [ns]{.smallcaps} = nonsignificant; [lv]{.smallcaps}5[fu]{.smallcaps}2 = leucovorin calcium ([fa]{.smallcaps}), 5-[fu; eortc]{.smallcaps} = European Organization for Research and Treatment of Cancer; [fufa]{.smallcaps} = 5-[fu]{.smallcaps}, [fa; fufox]{.smallcaps} = 5-[fu]{.smallcaps}, [fa]{.smallcaps}, oxaliplatin; [folfox]{.smallcaps} (appended digit indicates regimen variation) = [fa]{.smallcaps}, 5-[fu]{.smallcaps}, oxaliplatin; [folfiri]{.smallcaps} = [fa]{.smallcaps}, 5-[fu]{.smallcaps}, irinotecan; [ifl]{.smallcaps} = irinotecan, 5-[fu]{.smallcaps}, leucovorin calcium ([fa]{.smallcaps}); [irox]{.smallcaps} = irinotecan, oxaliplatin; [gercor]{.smallcaps} = Groupe Coopérateur Multidisciplinaire en Oncologie; [sicog]{.smallcaps} = Southern Italy Cooperative Oncology Group; [irifafu]{.smallcaps} = irinotecan, [fa]{.smallcaps}, 5-[fu; oxafafu]{.smallcaps} = oxaliplatin, [fa]{.smallcaps}, 5-[fu; goim]{.smallcaps} = Gruppo Oncologico Italia Meridionale; [folfoxiri]{.smallcaps} = [fa]{.smallcaps}, 5-[fu]{.smallcaps}, oxaliplatin, irinotecan; [gono]{.smallcaps} = Gruppo Oncologico Nord Ovest; [oxafafu]{.smallcaps} = oxaliplatin, [fa]{.smallcaps}, 5-[fu; fafu]{.smallcaps} = [fa]{.smallcaps}, 5-[fu; ecog]{.smallcaps} = Eastern Cooperative Oncology Group; [cpt]{.smallcaps}-11 = irinotecan.

###### 

Practitioner responses to eight items on the practitioner feedback survey

                                                                                                                                    *Percentage who*                     
  --------------------------------------------------------------------------------------------------------------------------------- ------------------------- ---------- ---------------------------------
  The rationale for developing a clinical practice guideline, as stated in the "Choice of Topic" section of the report, is clear.   100                       ---        ---
  There is a need for a clinical practice guideline on this topic.                                                                  89                        11         ---
  The literature search is relevant and complete.                                                                                   78                        22         ---
  The results of the trials described in the report are interpreted according to my understanding of the data.                      89                        11         ---
  The draft recommendations in this report are clear.                                                                               78                        17         6
  I agree with the draft recommendations as stated.                                                                                 83                        11         6
  This report should be approved as a practice guideline.                                                                           89                        6          6
                                                                                                                                    *Very likely or likely*   *Unsure*   *Not at all likely or unlikely*
  If this report were to become a practice guideline, how likely would you be to make use of it in your own practice?               67                        11         11

Cancer Care Ontario's Program in Evidence-based Care is sponsored by Cancer Care Ontario and the Ministry of Health and Long-Term Care.

APPENDIX ATreatment options (refer to Appendix B for recommended dosages and schedules)First-line treatment alternativesSecond-line treatment alternatives [folfiri]{.smallcaps} (combination 5-[fu]{.smallcaps}/[fa]{.smallcaps}/irinotecan) [folfox]{.smallcaps} (combination 5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin), after first-line [folfiri]{.smallcaps} [folfox]{.smallcaps} (combination 5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin) [folfiri]{.smallcaps} (combination 5-[fu]{.smallcaps}/[fa]{.smallcaps}/irinotecan), after first-line [folfox]{.smallcaps} de Gramont schedule (infusional 5-[fu]{.smallcaps}/[fa]{.smallcaps}) [folfox]{.smallcaps} (combination 5-[fu]{.smallcaps}/[fa]{.smallcaps}/oxaliplatin), plus bevacizumab Raltitrexed Irinotecan alone Capecitabine

APPENDIX BDosing by trial*ReferenceRegimen (mg/m[@b2-co13_5p173]daily, frequency)*First-line treatment Lévi *et al.,* 1994 [@b7-co13_5p173] ([iocc]{.smallcaps} trial)5-[fu]{.smallcaps} 600, [fa]{.smallcaps} 300, oxaliplatin 20, days 1--5, every 21 days (16-day intermission) via programmable pump\
Arm A: flat infusion\
Arm B: [cm]{.smallcaps} infusion (5-[fu]{.smallcaps}/[fa]{.smallcaps} peak at 04:00 hours; oxaliplatin peak at 16:00 hours) Lévi *et al.,* 1997 [@b8-co13_5p173] ([iocc]{.smallcaps} trial)5-[fu]{.smallcaps} 600, [fa]{.smallcaps} 300, oxaliplatin 20, days 1--5, every 21 days (16-day intermission)\
Arm A: flat infusion\
Arm B: [cm]{.smallcaps} infusion Buechele *et al.,* 2000, Germany [@b9-co13_5p173]Oxaliplatin 50, 2-hour infusion + [fa]{.smallcaps} 500, 2-hour infusion + 5-[fu]{.smallcaps} 2000, 24-hour infusion; days 1, 8, 15, and 22; every 36 days versus\
Bolus 5-[fu]{.smallcaps}/[fa]{.smallcaps} (Mayo Clinic regimen) de Gramont *et al.,* 2000 [@b10-co13_5p173]Oxaliplatin 85, 2-hour infusion, day 1 + 5-[fu]{.smallcaps} 400 bolus, then 600 continuous infusion, days 1 and 2 + [fa]{.smallcaps} 200, continuous infusion, days 1 and 2, every 2 weeks versus\
5-[fu]{.smallcaps} 400 bolus, then 600 continuous infusion, days 1 and 2 + [fa]{.smallcaps} 200, continuous infusion, days 1 and 2, every 2 weeks ([lv]{.smallcaps}5[fu]{.smallcaps}2 regimen) Giacchetti *et al.,* 2000 [@b11-co13_5p173]Oxaliplatin 125, 6-hour infusion, day 1 + 5-[fu]{.smallcaps} 700 + [fa]{.smallcaps} 300, [cm]{.smallcaps} infusion; days 1--5; every 3 weeks versus 5-[fu]{.smallcaps} 700 + [fa]{.smallcaps} 300, [cm]{.smallcaps} infusion, days 1--5, every 3 weeks Giacchetti *et al.,* 2002 [@b12-co13_5p173] ([eortc]{.smallcaps} trial)Oxaliplatin 25, [cm]{.smallcaps} infusion (peak at 16:00), 5-[fu]{.smallcaps} 750, [cm]{.smallcaps} infusion (peak at 04:00), [fa]{.smallcaps} 300, [cm]{.smallcaps} infusion (peak at 04:00); all three drugs given daily for 4 days and repeated every 2 weeks versus\
Oxaliplatin 100, 2-hour infusion, day 1; 5-[fu]{.smallcaps} 1500, 22-hour infusion, daily for 2 days; [fa]{.smallcaps} 600, 2-hour infusion daily for 2 days; repeat every 2 weeks ([folfox]{.smallcaps}2) Grothey *et al.,* 2002, Germany [@b13-co13_5p173]Oxaliplatin 50, 2-hour infusion + 5-[fu]{.smallcaps} 2000, 24-hour infusion + [fa]{.smallcaps} 500, 24-hour infusion; days 1, 8, 15, and 22; every 5 weeks ([fufox]{.smallcaps}) versus\
5-[fu]{.smallcaps} 425 bolus + [fa]{.smallcaps} 20, days 1--5, every 29 days (Mayo) Colucci *et al.,* 2003 [@b14-co13_5p173] ([goim]{.smallcaps} trial)Oxaliplatin 85, day 1; [fa]{.smallcaps} 100, 2-hour infusion, days 1 and 2; 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600, 22-hour infusion, days 1 and 2; every 2 weeks versus\
Irinotecan 180, day 1; [fa]{.smallcaps} 100, 2-hour infusion, days 1 and 2; 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600, 22-hour infusion, days 1 and 2; every 2 weeks Goldberg *et al.,* 2004 [@b15-co13_5p173] (Intergroup N9741 trial)Oxaliplatin 85, day 1, followed by 5 [fu]{.smallcaps} - 400 bolus + 600 22-hour infusion, days 1 and 2; [fa]{.smallcaps} 200, days 1 and 2; every 2 weeks (de Gramont [folfox]{.smallcaps}4) versus\
Irinotecan 125 + 5-[fu]{.smallcaps} 500 + [fa]{.smallcaps} 20; days 1, 8, 15, and 22; every 6 weeks (Saltz [ifl]{.smallcaps}) versus\
Oxaliplatin 85, day 1 + irinotecan 200, day 1; every 3 weeks (Wasserman [irox]{.smallcaps}) Tournigand *et al.,* 2004[@b16-co13_5p173] ([gercor]{.smallcaps} trial)First-line [folfiri]{.smallcaps}: irinotecan 180 2-hour infusion, day 1; [fa]{.smallcaps} 200 2-hour infusion, day 1; 5-[fu]{.smallcaps} 400 bolus, day 1; followed by 5-[fu]{.smallcaps} 2400--3000 48-hour infusion, day 2; every 2 weeks until progression, then follow with second-line [folfox]{.smallcaps}6 (as below) versus\
First-line [folfox]{.smallcaps}6: oxaliplatin 100 2-hour infusion, day 1; [fa]{.smallcaps} 200 2-hour infusion, day 1; 5-[fu]{.smallcaps} 400 bolus, day 1; followed by 5-[fu]{.smallcaps} 2400--3000 48-hour infusion, day 2; every 2 weeks until progression, then follow with second-line [folfiri]{.smallcaps} (as above) Comella *et al.,* 2005 [@b31-co13_5p173] ([sicog]{.smallcaps})[irifafu]{.smallcaps}: irinotecan 200 intravenously, day 1; [fa]{.smallcaps} 250 intravenously, followed by 5-[fu]{.smallcaps} 850, day 2 versus High-dose [oxafafu]{.smallcaps}: oxaliplatin 100, day 1; followed by [fa]{.smallcaps} 250 and 5-[fu]{.smallcaps} 1050, day 2 versus\
Low-dose [oxafafu]{.smallcaps}: oxaliplatin 85, day 1; [fa]{.smallcaps} 250 and 5-[fu]{.smallcaps} 850, day 1 Colucci *et al.,* 2005 [@b32-co13_5p173] ([goim]{.smallcaps})[folfiri]{.smallcaps}: irinotecan 180, day 1; [fa]{.smallcaps} 100 2-hour infusion, 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2 versus\
[folfox]{.smallcaps}4: oxaliplatin 85, day 1; irinotecan 180, day 1; [fa]{.smallcaps} 100 2-hour infusion, 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2 Falcone *et al.,* 2006 [@b33-co13_5p173] ([gono]{.smallcaps})[folfoxiri]{.smallcaps} : oxaliplatin 85, day 1; irinotecan 165, day 1; 5-[fu]{.smallcaps} 3200 48-hour infusion starting on day 1; l-[fa]{.smallcaps} 200, day 1; every 2 weeks versus\
[folfiri]{.smallcaps}: irinotecan 180, day 1; l-[lv]{.smallcaps} 100, days 1 and 2; 5-[fu]{.smallcaps} 400 bolus, days 1 and 2; followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2; every 2 weeks\
At progression on [folfiri]{.smallcaps}, a [folfox]{.smallcaps} regimen was recommended Hospers *et al.,* 2006 [@b34-co13_5p173][oxafafu]{.smallcaps}: oxaliplatin 85 2-hour infusion, [fa]{.smallcaps} 200 1-hour infusion, 5-[fu]{.smallcaps} 2600 24-hour infusion, day 1, every 2 weeks versus[fafu]{.smallcaps}: 5-[fu]{.smallcaps} 425, days 1--5; [fa]{.smallcaps} 20, days 1--5; every 4 weeks Souglakos *et al.,* 2006 [@b35-co13_5p173] ([horg]{.smallcaps})[folfoxiri]{.smallcaps}: oxaliplatin 65, day 2; irinotecan 150, day 1; [fa]{.smallcaps} 200, days 2 and 3; 5- [fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 2 and 3 versus\
[folfiri]{.smallcaps}: irinotecan 180, day 1; [fa]{.smallcaps} 200, days 2 and 3; 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 2 and 3 Stanculeanu *et al.,* 2006 [@b36-co13_5p173][folfox]{.smallcaps} 4: oxaliplatin 85, day 1; [fa]{.smallcaps} 200, days 1 and 2; 5- [fu]{.smallcaps} 400 bolus, followed by 5- [fu]{.smallcaps} 600 22-hour infusion, days 1 and 2; every 15 days versus\
[folfiri]{.smallcaps}: irinotecan 180, [fa]{.smallcaps} 400, 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 2400 46-hour infusion, every 15 days versus\
[irox]{.smallcaps}: irinotecan 300, day 1; oxaliplatin 85, day 2; every 3 weeks Tournigand *et al.,* 2006 [@b37-co13_5p173] ([gercor]{.smallcaps})[folfox]{.smallcaps} 4: oxaliplatin 85 2-hour infusion, day 1; [fa]{.smallcaps} 2-hour infusion (either 100 l-[lv]{.smallcaps} or 200 dl-[lv]{.smallcaps}), 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2; every 2 weeks versus\
[folfox]{.smallcaps}7 (6 cycles) → [lv]{.smallcaps}5[fu]{.smallcaps}2 (12 cycles) → [folfox]{.smallcaps}7 (6 cycles)\
[folfox]{.smallcaps}7: oxaliplatin 130 2-hour infusion, day 1; [fa]{.smallcaps} 2-hour infusion (either l-[lv]{.smallcaps} 200 or dl-[lv]{.smallcaps} 400), followed by 5-[fu]{.smallcaps} 2400 46-hour infusion; every 2 weeks\
[lv]{.smallcaps}5[fu]{.smallcaps}2: [fa]{.smallcaps} 2-hour infusion (either l-[lv]{.smallcaps} 200 or dl-[lv]{.smallcaps} 400), 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 3000 46-hour infusion, every 2 weeksSecond-line treatment Rothenberg *et al.,* 2003 [@b30-co13_5p173] (EFC4584 trial)Treatment given as second-line to [ifl]{.smallcaps}\
Oxaliplatin 85 2-hour infusion, day 1; 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2; every 2 weeks ([folfox]{.smallcaps}4) versus\
5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2; [fa]{.smallcaps} 200; every 2 weeks ([lv]{.smallcaps}5[fu]{.smallcaps}2) Garay *et al.,* 2003[@b17-co13_5p173] (Sanofi/Memorial Sloan Kettering Cancer Centre crossover trial)Treatment given as second-line to 5-[fu]{.smallcaps} + irinotecan ± [fa]{.smallcaps}\
Oxaliplatin 85 2-hour infusion, day 1; 5-[fu]{.smallcaps} 400 bolus; followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2; every 2 weeks ([folfox]{.smallcaps}4) versus\
5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2; [fa]{.smallcaps} 200; every 2 weeks ([lv]{.smallcaps}5[fu]{.smallcaps}2) Giantonio *et al.,* 2005 [@b38-co13_5p173] ([ecog]{.smallcaps})[folfox]{.smallcaps} 4 + bevacizumab: bevacizumab 10 mg/kg intravenously, biweekly; oxaliplatin 85, day 1; [fa]{.smallcaps} 200 2-hour infusion, 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2 versus\
[folfox]{.smallcaps}4: oxaliplatin 85, day 1; [fa]{.smallcaps} 200 2-hour infusion, 5-[fu]{.smallcaps} 400 bolus, followed by 5-[fu]{.smallcaps} 600 22-hour infusion, days 1 and 2 versus\
Bevacizumab: bevacizumab 10 mg/kg intravenously, biweekly Pitot *et al.,* 2005 [@b39-co13_5p173] (N9841)Irinotecan → [folfox]{.smallcaps}4 versus [folfox]{.smallcaps}4 → irinotecan\
Irinotecan 350, day 1, every 3 weeks (reduced to 300 for [ecog]{.smallcaps} performance status 2, age ≥ 70, or prior pelvic radiation)\
[folfox]{.smallcaps}4: oxaliplatin 85, [fa]{.smallcaps} 200, 5-[fu]{.smallcaps} 400 bolus, followed by 600 22-hour infusion, days 1 and 2, every 2 weeks[^2]

[^1]: Please see the Cancer Care Ontario Program in Evidence-Based Care's Web site for a complete list of Gastrointestinal Cancer Disease Site Group members ([www.cancercare.on.ca/index_AboutthePEBC.htm\#dsg](www.cancercare.on.ca/index_AboutthePEBC.htm#dsg)).

[^2]: [iocc]{.smallcaps} = International Organization Against Cancer; 5-[fu]{.smallcaps} = 5-fluorouracil; [fa]{.smallcaps} = folinic acid; [cm]{.smallcaps} = chronomodulated; [eortc]{.smallcaps} = European Organization for Research and Treatment of Cancer; [goim]{.smallcaps} = Gruppo Oncologico Italia Meridionale; [gercor]{.smallcaps} = Groupe Coopérateur Multidisciplinaire en Oncologie; [sicog]{.smallcaps} = Southern Italy Cooperative Oncology Group; l-[fa]{.smallcaps} = levo-folinic acid; [gono]{.smallcaps} = Gruppo Oncologico Nord Ovest; l-[lv]{.smallcaps} = levo-leucovorin calcium; [horg]{.smallcaps} = Hellenic Oncology Research Group; dl-[lv]{.smallcaps} = racemic leucovorin calcium; [ecog]{.smallcaps} = Eastern Cooperative Oncology Group.
